Cargando…

Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes

BACKGROUND: A number of non‐low‐density lipoprotein cholesterol lipid abnormalities are associated with type 2 diabetes and insulin resistance, which may lead practitioners to use medications targeting these abnormal lipid fractions despite a lack of evidence or guideline recommendations. METHODS AN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnold, Suzanne V., Gosch, Kensey, Wong, Nathan D., Hejjaji, Vittal, Goyal, Abhinav, Leiter, Lawrence A., Kosiborod, Mikhail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375067/ https://www.ncbi.nlm.nih.gov/pubmed/32704552 http://dx.doi.org/10.1002/edm2.126

Ejemplares similares

Comanagement of Risk Factors in Patients With Coronary Artery Disease: Insights From the APPEAR Study
por: Hejjaji, Vittal, et al.
Publicado: (2020)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study
por: Malik, Ali O., et al.
Publicado: (2022)

Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
por: Krähenbühl, Stephan, et al.
Publicado: (2016)

Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry(®)
por: Arnold, Suzanne V., et al.
Publicado: (2017)

LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA
por: Pan, Yuesong, et al.
Publicado: (2022)

Eligibility of patients with type 2 diabetes for sodium‐glucose co‐transporter‐2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry
por: Wittbrodt, Eric, et al.
Publicado: (2019)

Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
por: Karalis, Dean G., et al.
Publicado: (2012)

Are we running out of fish? Fish, health and sustainability
por: Khetan, Aditya, et al.
Publicado: (2023)

The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction
por: Arnold, Suzanne V, et al.
Publicado: (2014)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

What Do US Physicians and Patients Think About Lipid‐Lowering Therapy and Goals of Treatment? Results From the GOULD Registry
por: Arnold, Suzanne V., et al.
Publicado: (2021)

Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease
por: Peterson, Benjamin E., et al.
Publicado: (2023)

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
por: Kastelein, John J.P., et al.
Publicado: (2017)

Bioactivity of Dietary Polyphenols: The Role in LDL-C Lowering
por: Sun, Peng, et al.
Publicado: (2021)

Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid Measure is Preferred When Calculated LDL Is Inaccurate?
por: Baruch, Lawrence, et al.
Publicado: (2013)

Comparisons of abdominal wall reconstruction for ventral hernia repairs, open versus robotic
por: Nguyen, Barbara, et al.
Publicado: (2021)

Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub‐analysis of ODYSSEY COMBO II
por: Leiter, Lawrence A., et al.
Publicado: (2017)

Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register
por: Karlsson, Sofia Axia, et al.
Publicado: (2018)

LDL-C: lower is better for longer—even at low risk
por: Penson, Peter E., et al.
Publicado: (2020)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect
por: Hörl, Gerd, et al.
Publicado: (2016)

Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?: Results from the DA VINCI study
por: Siostrzonek, Peter, et al.
Publicado: (2021)

Case report: Coronary atherosclerosis in a patient with long-standing very low LDL-C without lipid-lowering therapy
por: Mottola, Giorgio, et al.
Publicado: (2023)

Chronic Kidney Disease and Health Status Outcomes Following Acute Myocardial Infarction
por: Navarro, Mark A., et al.
Publicado: (2016)

A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control
por: Turner, Barbara J, et al.
Publicado: (2011)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
por: Bongaerts, Brenda, et al.
Publicado: (2021)

LDL retention time in plasma can be -based on causation- estimated by the lipid composition of LDL and other lipoproteins
por: Jansen, Martin, et al.
Publicado: (2022)

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
por: Lewis, Gregory D., et al.
Publicado: (2023)

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
por: Rikhi, Rishi, et al.
Publicado: (2022)

The lack of association between different LDL‐C levels and oxidized LDL in patients with type 2 diabetes
por: Rabizadeh, Soghra, et al.
Publicado: (2023)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Awareness, Treatment, and Control of LDL Cholesterol Are Lower Among U.S. Adults With Undiagnosed Diabetes Versus Diagnosed Diabetes
por: Brown, Todd M., et al.
Publicado: (2013)

Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins
por: Sakamoto, Kentaro, et al.
Publicado: (2015)

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study
por: Komiya, Ichiro, et al.
Publicado: (2021)

Effectiveness of Medical Student Counseling for Hospitalized Patients Addicted to Tobacco (MS-CHAT): a Randomized Controlled Trial
por: Satish, Priyanka, et al.
Publicado: (2023)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl
por: Robinson, Jennifer G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_endjkp40itgg3q5k0135cm90k0